ArticleCureus2026
Impact of Pulmonary Rehabilitation on Quality of Life in Patients With Chronic Obstructive Pulmonary Disease: A Prospective Observational Cohort Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic obstructive pulmonary disease (COPD) is a long-term respiratory disorder characterized by persistent airflow limitation due to structural changes in the airways and lung parenchyma, leading to progressive symptoms and functional impairment. This study aimed to evaluate the association of pulmonary rehabilitation (PR) with health-related quality of life (QoL), symptom burden, and functional status among patients with COPD.
methodsA prospective observational cohort study was conducted among patients with COPD attending the outpatient department of Government Medical College, Datia. Participants receiving PR as part of routine clinical management and providing informed consent were enrolled and followed prospectively. Diagnosis was confirmed through clinical evaluation and spirometry, and patients were classified according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 categories (A, B, and E). Baseline assessments included the St. George's Respiratory Questionnaire (SGRQ) for COPD patients, the COPD Assessment Test (CAT), and pulmonary function tests. Patients participated in an eight-week supervised PR program conducted twice weekly, followed by continuation of home-based exercises for at least five days per week. Follow-up assessments were performed six months after enrollment. Data were analyzed using the Statistical Package for the Social Sciences software, version 26 (IBM Corp., Armonk, NY).
resultsA total of 107 participants were included, with a mean age of 62.5 ± 6.2 years. Most were male participants (82, 76.6%). GOLD Category E accounted for 69 (64.5%) participants and Category B for 38 (35.5%). Moderate airflow limitation (GOLD Grade 2) was present in 76 (71.0%) participants. At six-month follow-up, significant improvements were observed in QoL measures, including the SGRQ total score (p < 0.001) and all SGRQ domains (p < 0.001). CAT scores decreased significantly (p < 0.001). No statistically significant change was observed in forced expiratory volume in one second (% predicted) (p = 0.067).
conclusionParticipation in PR was associated with significant improvements in QoL, symptom burden, and functional status among patients with COPD, despite no significant changes in spirometric parameters. These findings support the integration of PR into comprehensive COPD care. Further multicentric studies with control groups and longer follow-up are needed to evaluate long-term effectiveness and identify optimal rehabilitation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.